CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Drug approved for neurotrophic keratitis

The US Food and Drug Administration has approved Oxervate for the treatment of a rare disease of the cornea


For the first time, the US Food and Drug Administration (FDA) has approved a drug for the treatment of neurotrophic keratitis, a degenerative disease that results from the loss of corneal sensation.

The approved medication is Oxervate, a topical eye drop containing cenegermin.

The safety and effectiveness of the drug was studied in 151 patients with neurotrophic keratitis in two eight week trials.

Across both studies, complete corneal healing in eight weeks was demonstrated in 70% of patients treated with Oxervate compared to 28 percent of patients treated without the active ingredient of Oxervate.

The most common adverse reactions observed during the trial were watery eyes, enlarged blood vessels in the white of the eyes and eye inflammation.

The prevalence of neurotrophic keratitis has been estimated to be fewer than five cases in 10,000 individuals.